FDA 483 - Unknown Company - March 18, 2011

This FDA Form 483 document details observations made during an inspection of a pharmaceutical manufacturing facility. The inspection revealed several deficiencies related to the production of sterile drug products.

Observation 1 indicates a failure to establish an adequate system for monitoring environmental conditions within the aseptic processing area. This suggests potential risks to product sterility due to uncontrolled environmental factors.

Observation 2 highlights that the sterilization process for equipment used in sterile drug product production was not adequately validated. This is a critical finding as it directly impacts the sterility assurance of the final product.

Observation 3 notes that the firm did not conduct adequate investigations into batch discrepancies and failures. This indicates a weakness in their quality system, potentially allowing recurring issues to go unaddressed and impacting overall product quality and safety.

Finally, Observation 4 states that the firm lacked proper controls to prevent contamination during the manufacturing process. This broad observation suggests systemic issues in contamination control, posing a significant risk to product integrity and patient safety.

Collectively, these observations point to significant deficiencies in the facility's quality system, aseptic processing controls, sterilization validation, and contamination prevention, all of which are critical for the manufacture of safe and effective sterile drug products.